Volume 30, Number 1—January 2024
Dispatch
Tuberculosis Diagnostic Delays and Treatment Outcomes among Patients with COVID-19, California, USA, 2020
Table 2
Disease-associated hospitalization† | No. admissions | Median duration, d (IQR) | Range, d | Cumulative hospital days | ICU and intubation | In-hospital death‡ |
---|---|---|---|---|---|---|
Total | 73 | 12.0 (7.0‒21.0) | 1‒139 | 1,324 | 14 | 6 |
TB only | 35 (47.9) | 13.0 (8.0‒21.0) | 1‒74 | 634 | 5 (14.3) | 0 (0.0) |
TB and COVID-19§ | 23 (31.5) | 10.0 (5.0‒20.0) | 1‒139 | 392 | 5 (21.7) | 4 (17.4) |
COVID-19 only | 15 (20.5) | 12.0 (6.0‒26.0) | 3‒68 | 298 | 4 (26.7) | 2 (13.3) |
*TB–COVID-19 co-infected patients had TB and COVID-19 diagnoses within 120 d of each other, whereby >1 of the diseases was diagnosed in 2020. Included California jurisdictions were Alameda, Los Angeles, Orange, Sacramento, San Diego, and Santa Clara Counties. Values are no. (%) except where indicated. ICU, intensive care unit; TB, tuberculosis. †Based on the timing of hospitalization and diagnosis for each disease. Distinct TB-associated and COVID-19–associated hospitalizations must have occurred >14 d apart. Persons who were hospitalized at any point had an average 1.3 hospitalizations each. ‡Patients who died in hospital had admission durations of 10‒57 d. §Concurrent TB and COVID-19 were addressed in same hospital stay.
1These first authors contributed equally to this article.